See the below visualization of ASC Technology used for developing our Covid-19 vaccine.

Our technology has been patented in USA, Europe, China, Japan and Turkey.

• Sahillioğlu AC*, Sümbül F*, Özören N** and Haliloğlu T**, “Structural and Dynamics Aspects of ASC Speck Assembly”, 2014, Structure., Dec 2;22(12):1722-34. doi: 10.1016/j.str.2014.09.011. Epub 2014 Nov 6.
• Sahillioğlu AC and Özören N, “Artificial Loading of ASC Specks with Cytosolic Antigens”, PLoS One. 2015 Aug 10;10(8):e0134912. doi: 10.1371/journal.pone.0134912. eCollection 2015.
• Eren E, Berber M and Özören N, “NLRC3 protein inhibits inflammation by disrupting NALP3 inflammasome assembly via competition with the adaptor protein ASC for pro-caspase-1 binding”, J Biol Chem. 2017 Jun 5. pii: jbc.M116.769695. doi: 10.1074/jbc.M116.769695. PMID: 28584053
• Franchi, L., Özören, N., Body-Malapel, M., Jagirdar, R., & Núñez, G. (2006). Cytosolic Recognition of Intracellular Bacteria by ASC and Ipaf Overcomes Endotoxin Tolerance Through Induction of Potent IL-1β Secretion. Inflammatory Bowel Diseases, 12, S21. doi: 10.1097/00054725-200604002-00043.
• Özören, N., Masumoto, J., Franchi, L., Kanneganti, T., Body-Malapel, M., & Erturk, I. et al. (2006). Distinct Roles of TLR2 and the Adaptor ASC in IL-1 /IL-18 Secretion in Response to Listeria monocytogenes. The Journal Of Immunology, 176(7), 4337-4342. doi: 10.4049/jimmunol.176.7.4337.
• Franchi, L., Amer, A., Body-Malapel, M., Kanneganti, T., Özören, N., & Jagirdar, R. et al. (2006). Cytosolic flagellin requires Ipaf for activation of caspase-1 and interleukin 1β in salmonella-infected macrophages. Nature Immunology, 7(6), 576-582. doi: 10.1038/ni1346.
• Kanneganti, T., Özören, N., Body-Malapel, M., Amer, A., Park, J., & Franchi, L. et al. (2006). Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature,440(7081), 233-236. doi: 10.1038/nature04517